Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 10/12/16 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
58 |
| 10/11/16 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/29/16 | S-3 | Registration statement for specified transactions by certain issuers |
|
47 | |
| 09/13/16 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
56 | |
| 09/12/16 | 8-K | Current report filing |
|
77 | |
| 09/09/16 | EFFECT | Notice of Effectiveness |
|
1 | |
| 09/08/16 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/08/16 | S-3/A | Registration statement for specified transactions by certain issuers |
|
47 | |
| 09/07/16 | UPLOAD | SEC-generated letter |
|
2 | |
| 08/26/16 | S-3 | Registration statement for specified transactions by certain issuers |
|
99 |
